Our Impact

Precision killing of bacteria has the impact to revolutionise the management of untreatable and difficult-to-treat infections as well as complex diseases directly impacted by the human microbiota. 

Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.

$50M Series A Raised

SNIPR Biome raises $50M in one of the largest SERIES A in Europe from 4 large European funds to advance CRISPR-based microbiome drugs to human clinical trials.

25+ Scientists

Since its inception in August 2017, SNIPR Biome has over the course of 2 years grown to a team of more than 25 - predominantly PhDs.

Several Patent Families

The SNIPR Biome scientists have made several innovative and novel discoveries which are being protected in several separate patent families – seven of which have already granted as US patents (US9701964, US10195273, US10300138, US10300139, US10363308, US10463049, and US10506812).